SHAREHOLDER NEWS: Johnson Fistel Investigates Proposed Sale of ImmunoGen

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of ImmunoGen, Inc. (NASDAQ: IMGN) breached their fiduciary duties in connection with the proposed sale of the Company to AbbVie.

You can click or copy and paste the following link to join this investigation:

https://www.johnsonfistel.com/investigations/ImmunoGen-co

On November 30, 2023, ImmunoGen announced that it had entered a deal to merge with AbbVie. Under the terms of the deal, ImmunoGen shareholders will receive $31.26 per share in cash.

If you are a shareholder of ImmunoGen and believe the proposed buyout price is too low or you're interested in learning more about the investigation, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If emailing, please include a phone number.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com.

Johnson Fistel, LLP is a shareholder rights law firm representing individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information, visit their website http://www.johnsonfistel.com.

Attorney advertising.

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices.         

Contact:
Johnson Fistel, LLP
501 W. Broadway, Suite 800, San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471
[email protected] or [email protected]